StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
DRAGARWQ.BO$5100.60-2.67%
Fair $5100.60+0.0%

DRAGARWQ.BO

Dr. Agarwal's Eye Hospital Limited

Healthcare / Medical Care FacilitiesBSE

$5100.60

-136.45 (-2.67%)

Fairly Valued+0.0%Fair Value $5100.60Fund rank 24/100 · Data gapFallback financials|
SA 44/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $184.5M · quality 36.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · DRAGARWQ.BOLocal privado en este navegador · Dr. Agarwal's Eye Hospital Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$24.7B

P/E

34.6x

↑

EV/EBITDA

18.4x

↑

ROE

20.2%

↑

Gross Margin

78.4%

↑

Debt/Equity

0.94

↑
52-Week Range$5101
$4142$6392

TradingView lightweight chart

DRAGARWQ.BO price, volumen y niveles de valoración

Último $4,974Periodo -17.7%
Fair value: $5,101

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+20.8%

FCF CAGR

—

FCF margin

9.9%

FCF / Net income

0.67x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.70B · net income $701.0M · FCF $467.5M

2023-FY → 2026-FY

Gross margin

78.4%+1.3% pts

Operating margin

21.0%-0.2% pts

Net margin

14.9%+1.1% pts

FCF margin

9.9%+10.2% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$4.70B$4.70B$3.97B$3.17B$2.67B
Net Income$701.0M$701.0M$546.5M$463.6M$369.2M
EBITDA$1.51B$1.51B$1.24B$959.6M$763.8M
EPS——116.2898.6478.55
Gross Margin78.4%78.4%77.4%77.7%77.1%
Operating Margin21.0%21.0%19.9%20.9%21.2%
Net Margin14.9%14.9%13.8%14.6%13.8%
Balance Sheet
Debt/Equity0.940.941.591.712.05
Current Ratio1.231.23———
Cash Flow
Free Cash Flow$467.5M$467.5M$-93.0M$184.5M$-7.2M
Returns
ROE20.2%20.2%26.1%29.5%32.6%
Valuation
P/E34.6534.6535.63——
EV/EBITDA18.4018.4018.36——
P/B7.127.129.29——
Growth & Yield
Revenue Growth18.3%18.3%25.5%18.7%—
EPS Growth——17.9%25.6%—
Dividend Yield0.1%0.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +15.4%

Total return

+15.4%

Start / end P/E

n/dx → n/dx

EPS bridge

116.28 → n/d

Residual

+15.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.1%
Residual / FX / buybacks / cross-term+15.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.